Cloudbreak Pharmaceutical

Pre-clinical

Irvine, United StatesFounded 2015cloudbreakpharma.com

Founded in 2015 and headquartered in Irvine, California, Cloudbreak Pharmaceutical is a global biotech focused on transforming ophthalmic care through innovative drug development. The company has advanced its lead asset, CBT-001, into Phase 3 trials following a successful End-of-Phase 2 meeting with the FDA, positioning it as a potential first therapeutic for pterygium. Cloudbreak's strategy combines in-house R&D expertise with strategic regional partnerships, including agreements with Santen and Grand Pharma, to develop and commercialize its pipeline across major markets.

Founded

2015

AI Company Overview

Technology Platform

Two core platforms: 1) A proprietary formulation technology to deliver potent multi-kinase inhibitors as topical eye drops for anterior segment diseases, and 2) An Antibody-Drug Synergism (ADS) Platform for treating posterior segment ophthalmic diseases.

Opportunities

Cloudbreak has a first-mover opportunity to establish the pharmacological treatment paradigm for pterygium, a multi-million patient market with no approved drugs.

Its platform technologies could be applied to develop improved therapies for large, chronic ophthalmic markets like AMD and diabetic retinopathy.

Strategic partnerships in high-prevalence Asian markets provide a clear path to near-term commercialization and revenue.

Risk Factors

The company faces significant clinical risk as its lead asset, CBT-001, progresses through Phase 3 trials.

As a first-in-class therapy, it carries commercial and reimbursement risks associated with market education and adoption.

The company is also highly dependent on the success of a single asset, with earlier-stage pipeline programs facing intense competition in established markets.

Competitive Landscape

CBT-001 has no direct late-stage drug competitors for pterygium, competing only against surgical procedures. For its other pipeline programs in AMD and diabetic retinopathy, Cloudbreak would face entrenched competition from anti-VEGF therapies and newer agents, requiring demonstration of superior efficacy or delivery. The company's differentiation lies in its proprietary formulation expertise for topical delivery and its novel Antibody-Drug Synergism Platform.